Role of deferiprone in chelation therapy for transfusional iron overload

Blood

Volumn 102, Issue 1, 2003, Pages 17-24

  Hoffbrand, A Victor ^a   Cohen, Alan ^b   Hershko, Chaim ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; LIVER ENZYME; ZINC;

AGRANULOCYTOSIS; ARTHRALGIA; BLOOD TRANSFUSION; CHELATION THERAPY; DRUG EFFICACY; DRUG LIVER LEVEL; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEARING DISORDER; HUMAN; IRON EXCRETION; IRON HEART LEVEL; IRON LIVER LEVEL; IRON METABOLISM; IRON OVERLOAD; LIVER DYSFUNCTION; LIVER TOXICITY; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; ZINC DEFICIENCY;

EID: 0037630378     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1867     Document Type: Review

References (91)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2:27-30.
2. Borgna-Pignatti C, Carnelli V, Caruso V, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-231.
3. World Health Organisation Hereditary Diseases Programme. Guidelines for the Control of Haemoglobin Disorders Booklet. 1994; WHO/HDP/HB/GL/94.1.
4. Pippard MJ, Weatherall DJ. Oral iron chelation therapy for thalassaemia: an uncertain scene. Br J Haematol. 2000;111:2-5.
5. Balveer K, Pryor K, Wonke B. Combined oral and parenteral iron chelation in beta thalassaemia major. Med J Malaysia. 2001;55:493-497.
6. Modell B, Khan M, Darlison M. Survival in beta thalassaemia major in the United Kingdom: data from the U.K. Thalassaemia Register. Lancet. 2000;355:2051-2052.
7. Gabutti V, Piga A. Results of long-term iron chelating therapy. Acta Haematol. 1996;95:26-36.
8. Hider RC, Kontoghiorghes G, Silver J, Stockham MA. Pharmaceutically active hydroxypyridones. 1984. GB patent 21-46989.
9. Kontoghiorges GJ, Aldouri MA, Sheppard L, et al. 1-2-Dimethyl-3-hydroxypyrid-4-1, an orally active chelator for treatment of iron overload. Lancet. 1987;1:1294-1295.
10. Kontoghiorges GJ, Aldouri MA, Hoffbrand AV, et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-1. BMJ. 1987;295:1509-1512.
11. Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion-dependent thalassaemia: Indian trial. Br J Haematol. 1992;82:460-466.
12. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, et al. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 (L1), I: iron chelation and metabolic studies. Br J Haematol. 1990;76:295-300.
13. Al-Refaie FN, Wonke B, Hoffbrand AV, et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 (L1) in thalassemia major. Blood. 1992;80:593-599.
14. Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet. 1990;336:1275-1279.
15. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, et al. L1 (1-2-dimethyl-3-hydroxypyrid-4-1) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol. 1990;76:550-553.
16. Al-Refaie FN, Hoffbrand AV. Oral iron chelation therapy. Rec Adv Haematol. 1993;7:185-216.
17. Hershko C, Konijn AM, Link G. Iron chelators for thalssaemia. Br J Haematol. 1998;101:399-406.
18. Barman Balfour JA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in alpha thalassaemia major and other transfusion-dependent diseases. Drugs. 1999;3:553-578.
19. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332:918-922.
20. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417-423.
21. Maggio A, D'Amico GD, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cell Mol Dis. 2002;28:196-208.
22. Tondury P, Zimmermann A, Nielsen P, et al. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol. 1998;101;413-415.
23. Cohen AR, Galanello R, Piga A, et al. Long-term safety and efficacy of the oral iron chelator deferiprone [abstract]. Blood. 2000;96:443.
24. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79:2741-2748.
25. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361-364.
26. Olivieri NF. Iron chelating therapy. In: Hematology 2001. Washington, DC: Am Soc Hematol Educ Prog Book; 2001;52-61.
27. Matsui D, Klein J, Hermann C, et al, Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 in patients with thalassemia. Clin Pharmacol Ther. 1991;50:294-298.
28. Kontoghiorghes GJ, Goddard JG, Bartlett AN, et al. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1. Clin Pharmacol Ther. 1990;48:255-261.
29. Al-Refaie FN, Shephard LN, Nortey P, et al. Pharmacokinetics of the oral chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995;89:403-408.
30. Al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol. 1995;91:224-229.
31. Hoffbrand AV, Al-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood. 1998;91:295-300.
32. Kersten MJ, Lange R, Smeets MEP, et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol. 1996;73:247-252.
33. Del Vecchio GC, Crollo E, Schettini F, et al. Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting. Acta Haematol. 2000;104:99-102.
34. Collins AF, Fassos FF, Stobie S, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 (L1) in iron-loaded patients with sickle cell disease. Blood. 1994;83:2329-2333.
35. Grady RW, Berdoukas V, Rachmilewitz EA, et al. Iron chelation therapy: metabolic aspects of combining deferiprone and deferoxamine [abstract]. 11th International Conference on Oral Chelation in the Treatment of Thalassaemia Major and Other Diseases. Catania, Italy: 2001;74-78.
36. Grady RW, Berdoukas V, Rachmilewitz EA, et al. Combinations of desferrioxamine and deferiprone markedly enhance iron excretion [abstract]. Blood. 2002;100:241.
37. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J Clin Pathol. 1990;43:638-640.
38. Mazza P, Amurri B, Lazzari G, et al. Oral iron chelating therapy: a single center interim report on deferiprone (L1) in thalassaemia. Haematologica. 1998;83:496-501.
39. Cohen AR, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicenter study. Br J Haematol. 2000;108:305-312.
40. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118:330-336.
41. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia Blood. 1997;89:739-761.
42. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-573.
43. Olivieri NF, Brittenham GM. Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO) [abstract]. Blood. 1997;90:264.
44. Olivieri NF, Brittenham GN, Armstrong SAM, et al. First prospective randomized trials of the iron chelators deferiprone (L1) and deferoxamine [abstract]. Blood. 1995;86:249.
45. .) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-2179.
46. Pennell DJ, Bland JM, Deferiprone versus desferrioxamine in thalassaemia and T2 validation and utility [letter]. Lancet. 2003;361:183-184.
47. Anderson LJ, Wonke N, Prescott E, et al. Improved myocardial iron levels and ventricular function with oral deferiprone compared with subcutaneous desferrioxamine in thalassemia. Lancet. 2002;360:516-520.
48. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331: 574-578.
49. Davis BA, Porter JB. Long-term outcome of continuous 24-hour desferrioxamine infusion via in-dwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229-1236.
50. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239-252.
51. Shalev O, Repka T, Goldfarb A, et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassaemic and sickle red blood cells both in vitro and in vivo. Blood. 1995;86:2008-2013.
52. 14C-deferiprone in normal, thalassaemic and sickle red blood cells. Br J Haematol. 1999;105:1081-1083.
53. de Franchesi L, Shalev O, Piga A, et al. Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl co-transport activity. J Lab Clin Med. 1999;133:64-69.
54. Breuer W, Empers MJJ, Pootrakul P, Abramov A, Hershko C, Cabantchik I. Deferoxamine-chelatable iron, a component of serum non-transfusion-bound iron, used for assessing chelation therapy. Blood. 2001;97:792-798.
55. Link G, Konijn AM, Breuer W, Cabantchik I, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001;138:130-138.
56. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187-189.
57. Farmaki K, Anagnostopoulos G, Platis O, Gotsis E, Toulas P. Combined chelation therapy in patients with thalassemia major: a fast and effective method of reducing ferritin levels and cardiological complications [abstract]. Hematol J. 2002;3(suppl 1):79.
58. Alymara V, Bourantas DK, Chaidos A, et al. Combined iron chelation therapy with desferrioxamine and deferiprone in β-thalassemic patients [abstract]. Hematol J 2002;3(suppl 1):81.
59. Galanello R, Doneddu I, Dessi E, et al. Iron chelation in thalassemia major: combined treatment with deferiprone and deferoxamine [abstract]. 11th International Conference on Oral Chelation in the Treatment of Thalassemia and Other Diseases. Catania, Italy: 2001;73.
60. Kattamis, Kassou C, Ladis V, et al. Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia [abstract]. Blood. 2002;100:120a.
61. Aydinok Y, Nisli G, Kavakli K, et al. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey. Acta Haematol. 1999;102:17-21.
62. Al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol. 1994;53:298-301.
63. Cunningham JM, Al-Refaie FN, Hunter AE, et al. Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro. Eur J Haematol. 1994;52:176-179.
64. Hoyes K, Jones H, Abeysinghe R, Hider R, Porter J. In vivo and in vitro effects of 3-hydroxypyridin-4-1 chelators on murine hemopoiesis. Exp Hematol. 1993;21:86-92.
65. Hoffbrand AV. Oral iron chelation. Semin Hematol. 1996;33:1-8.
66. Kowdley KV, Kaplan MH. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med. 1998;339:468-469.
67. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100:17-21.
68. Callea F. Iron chelation with oral deferiprone in patients with thalassemia [letter]. N Engl J Med. 1998;339:1719-1711.
69. Carthew P, Smith AG, Hider RC, et al. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload with the hydroxypyridinine iron chelator CP94. Biometals. 1994;7:267-271.
70. Liu DY, Liu ZD, Hider RC. Oral iron chelators - development and application. Clin Haemat. 2002;15:364-384.
71. Hider RC, Choudhury R, Rai BL, et al. Design of orally active iron chelators. Acta Haematol. 1996;95:6-12.
72. Singh S, Epemolu RO, Dobbin PS, et al. Urinary metabolic profiles in human and rat of 1,2-dimethyl and 1,2-diethyl-3-hydroxypyrid-4-1. Drug Metab Dispos. 1992;20:256-261.
73. Porter JB, Abeusinghe RD, Hoyes KP, et al. Contrasting interspecies efficacy and toxicology of 1,2-dimethyl-3-hydroxypyrid-4-1, CP94, relates to different metabolism of the iron chelating site. Br J Haematol. 1993;85:159-168.
74. Porter JB, Singh S, Hoyes KP, et al. Lessons from preclinical and clinical studies with 1,2-dimethyl-3-hydroxypyrid-4-1, CP94 and related compounds. Adv Exp Med Biol. 1994;356:361-370.
75. Hershko C, Link G, Konijn AM, et al. The ironloaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med. 2002;139:50-58.
76. Wong A, Alder V, Robertson D, et al. Liver iron depletion and toxicity of the iron chelator deferiprone (L1 CP20) in the guinea pig. Bio Metals. 1997;10:247-256.
77. Wanless A, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. 2002;100:1566-1569.
78. Berdoukas V, Bohane T, Eagle C, et al. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). Transfus Sci. 2000;23:239-240.
79. Al-Refaie FN, Wonke B, Wickens DG, et al. Zinc concentration in patients with iron overload receiving iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 or deferoxamine. J Clin Pathol. 1994;47:657-660.
80. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long term trial with the oral iron chelator 1-2-dimethyl-3-hydroxypyrid-4-1 (L1), II: clinical observations. Br J Haematol. 1990;76:301-304.
81. Berkovitch M, Laxer R, Inman R, et al. Arthropathy in thalassaemia patients receiving deferiprone. Lancet. 1994;343:1471-1472.
82. Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassemic patients. Eur J Clin Pharmacol. 2001;56:915-922.
83. Mehta J, Singhal S, Revankar R, et al. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1 [letter]. Lancet. 1991;337:298.
84. Pradhan V, Badakese S, Ghosh K. Antihistone and other atoantibodies in β-thalassemia major patients receiving iron chelators. Acta Haematol. 2003;109:35-39.
85. Castriota-Scanderbeg A, Sacco M. Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). Br J Haematol. 1997;96;254-255.
86. Chioldo AA, Alberti PW, Sher GD, et al. Deferoxamine ototoxicity in an adult transfusion dependent population. J Otolaryngol. 1997;26:116-122.
87. Olivieri NF. Long-term therapy with deferiprone. Acta Haematol. 1996;95:37-48.
88. Addis A, Loebstein R, Koren G, Einarson TF. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Parmacol. 1999;55:1-6.
89. Hershko C, Hoffbrand AV. Iron chelation therapy. Rev Clin Exp Haematol. 2001;4:337-361.
90. Hippocrates. Hippocratic writings. Lloyd FER, ed. London, United Kingdom: Harmondsworth (Penguin): 1978;206.
91. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489-496.